BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nakayama EE, Kubota-Koketsu R, Sasaki T, Suzuki K, Uno K, Shimizu J, Okamoto T, Matsumoto H, Matsuura H, Hashimoto S, Tanaka T, Harada H, Tomita M, Kaneko M, Yoshizaki K, Shioda T. Anti-nucleocapsid antibodies enhance the production of IL-6 induced by SARS-CoV-2 N protein. Sci Rep 2022;12:8108. [PMID: 35577892 DOI: 10.1038/s41598-022-12252-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Yu H, Guan F, Miller H, Lei J, Liu C. The role of SARS-CoV-2 nucleocapsid protein in antiviral immunity and vaccine development. Emerg Microbes Infect 2023;12:e2164219. [PMID: 36583642 DOI: 10.1080/22221751.2022.2164219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Jurenka J, Nagyová A, Dababseh M, Mihalov P, Stankovič I, Boža V, Kravec M, Palkovič M, Čaprnda M, Sabaka P. Anti-SARS-CoV-2 Antibody Status at the Time of Hospital Admission and the Prognosis of Patients with COVID-19: A Prospective Observational Study. Infect Dis Rep 2022;14:1004-16. [PMID: 36547246 DOI: 10.3390/idr14060100] [Reference Citation Analysis]
3 Vu LD, Wallace S, Phan AT, Christofferson RC, Turner E, Parker S, Elkind-Hirsch K, Landry D, Stansbury A, Rose R, Nolan DJ, Lamers SL, Hirezi M, Ogden B, Cormier SA. Absence of antibody responses to SARS-CoV-2 N protein in COVID-19 vaccine breakthrough cases. Exp Biol Med (Maywood) 2022;247:1923-36. [PMID: 36408542 DOI: 10.1177/15353702221134097] [Reference Citation Analysis]
4 Duarte LF, Vázquez Y, Diethelm-varela B, Pavez V, Berríos-rojas R, White JA, Kalergis AM, Bueno SM, González PA. DIFFERENTIAL SARS-COV-2 ANTIGEN SPECIFICITY OF THE HUMORAL RESPONSE IN INACTIVATED VIRUS-VACCINATED, CONVALESCENT, AND BREAKTHROUGH SUBJECTS.. [DOI: 10.1101/2022.07.01.22277165] [Reference Citation Analysis]